BioSpace News Archive

In situ hybridization refers to a well-established set of methods for the visualization and detection of specific nucleic acid sequences in whole organisms, cytological preparations, and tissue sections.

BioScript Solutions® is pleased to announce that it has been recognized as one of Canada’s Best Managed Companies.

Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:45 a.m. ET.

Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24 th Annual Meeting of the American Society of Gene & Cell Therapy TSHA-104 increased COX1 activity in brain and muscle and restored elevation of blood lactate on exhaustive exercise in dose-dependent manner in SURF1 knockout mice

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced a partnership with LeadGen Labs, a custom synthesis and contract research organization

First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed the acquisition of Trapelo Health in April

-- First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million -- -- First-Quarter 2021 Orphan Segment Net Sales Increased 5 Percent to $257.5 Million; KRYSTEXXA ® (pegloticase injection) First-Quarter 2021 Net Sales Increased 14 Percent to $106.7 Million --

Increased 2021 Earnings Outlook on Strong Margin Expansion Board Authorizes New $3.75 Billion Share Repurchase Program Brent Shafer and Board Agree to Begin Search for Company’s Next CEO Shafer Expected to Continue to Serve Until Successor Appointed

The award will support young investigators interested in community-based participatory research whose projects address disparities and promote health equity in lung cancer

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will present at the 16th Annual Needham Technology & Media Conference, which will be held virtually.